id	sid	tid	token	lemma	pos
work_xsvwzurwvngfnj4ubi324mvlje	1	1	Donor	Donor	NNP
work_xsvwzurwvngfnj4ubi324mvlje	1	2	Lymphocyte	Lymphocyte	NNP
work_xsvwzurwvngfnj4ubi324mvlje	1	3	Infusion	Infusion	NNP
work_xsvwzurwvngfnj4ubi324mvlje	1	4	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	1	5	Beauty	beauty	NN
work_xsvwzurwvngfnj4ubi324mvlje	1	6	Is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	1	7	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	1	8	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	1	9	Eye	Eye	NNP
work_xsvwzurwvngfnj4ubi324mvlje	1	10	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	1	11	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	1	12	Beholder	Beholder	NNP
work_xsvwzurwvngfnj4ubi324mvlje	1	13	M.R.	M.R.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	1	Bishop	Bishop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	2	/	/	SYM
work_xsvwzurwvngfnj4ubi324mvlje	2	3	Biol	Biol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	4	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	5	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	6	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	7	19	19	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	8	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	2	9	2013	2013	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	10	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	2	11	847e850	847e850	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	12	849	849	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	13	Donor	Donor	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	14	Lymphocyte	Lymphocyte	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	15	Infusion	Infusion	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	16	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	2	17	Beauty	beauty	NN
work_xsvwzurwvngfnj4ubi324mvlje	2	18	Is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	2	19	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	20	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	2	21	Eye	Eye	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	22	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	23	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	2	24	Beholder	Beholder	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	25	Michael	Michael	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	26	R.	R.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	27	Bishop	Bishop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	28	*	*	NFP
work_xsvwzurwvngfnj4ubi324mvlje	2	29	Section	Section	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	30	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	31	Hematology	Hematology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	32	/	/	SYM
work_xsvwzurwvngfnj4ubi324mvlje	2	33	Oncology	Oncology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	34	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	2	35	University	University	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	36	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	37	Chicago	Chicago	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	38	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	2	39	Chicago	Chicago	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	40	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	2	41	Illinois	Illinois	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	42	Article	Article	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	43	history	history	NN
work_xsvwzurwvngfnj4ubi324mvlje	2	44	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	2	45	Received	receive	VBN
work_xsvwzurwvngfnj4ubi324mvlje	2	46	8	8	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	47	April	April	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	48	2013	2013	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	49	Accepted	accept	VBD
work_xsvwzurwvngfnj4ubi324mvlje	2	50	10	10	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	51	April	April	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	52	2013	2013	CD
work_xsvwzurwvngfnj4ubi324mvlje	2	53	In	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	54	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	2	55	issue	issue	NN
work_xsvwzurwvngfnj4ubi324mvlje	2	56	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	57	Biology	Biology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	58	Of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	2	59	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	60	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	2	61	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	62	Trans-	Trans-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	63	plantation	plantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	2	64	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	2	65	Bar	Bar	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	66	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	67	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	2	68	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	3	1	report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	2	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	3	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	3	4	retrospective	retrospective	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	5	analysis	analysis	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	6	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	7	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	3	8	effect	effect	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	9	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	10	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	11	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	12	dose	dose	VBP
work_xsvwzurwvngfnj4ubi324mvlje	3	13	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	14	initial	initial	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	15	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	16	lymphocyte	lymphocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	17	infusion	infusion	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	18	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	19	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	20	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	21	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	22	graft	graft	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	23	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	3	24	versus	versus	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	25	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	3	26	host	host	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	27	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	28	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	29	GVHD	GVHD	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	30	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	31	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	3	32	overall	overall	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	33	sur-	sur-	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	34	vival	vival	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	35	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	36	225	225	CD
work_xsvwzurwvngfnj4ubi324mvlje	3	37	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	3	38	who	who	WP
work_xsvwzurwvngfnj4ubi324mvlje	3	39	received	receive	VBD
work_xsvwzurwvngfnj4ubi324mvlje	3	40	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	41	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	42	relapsed	relapsed	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	43	hema-	hema-	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	44	tologic	tologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	3	45	malignancy	malignancy	NN
work_xsvwzurwvngfnj4ubi324mvlje	3	46	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	3	47	primarily	primarily	RB
work_xsvwzurwvngfnj4ubi324mvlje	3	48	at	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	3	49	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	3	50	Fred	Fred	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	51	Hutchison	Hutchison	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	52	Cancer	Cancer	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	53	Research	Research	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	54	Center	Center	NNP
work_xsvwzurwvngfnj4ubi324mvlje	3	55	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	56	1	1	CD
work_xsvwzurwvngfnj4ubi324mvlje	3	57	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	3	58	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	4	1	This	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	4	2	article	article	NN
work_xsvwzurwvngfnj4ubi324mvlje	4	3	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	4	4	important	important	JJ
work_xsvwzurwvngfnj4ubi324mvlje	4	5	from	from	IN
work_xsvwzurwvngfnj4ubi324mvlje	4	6	several	several	JJ
work_xsvwzurwvngfnj4ubi324mvlje	4	7	perspectives	perspective	NNS
work_xsvwzurwvngfnj4ubi324mvlje	4	8	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	4	9	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	4	10	which	which	WDT
work_xsvwzurwvngfnj4ubi324mvlje	4	11	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	4	12	will	will	MD
work_xsvwzurwvngfnj4ubi324mvlje	4	13	expound	expound	VB
work_xsvwzurwvngfnj4ubi324mvlje	4	14	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	5	1	However	however	RB
work_xsvwzurwvngfnj4ubi324mvlje	5	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	5	3	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	4	state-	state-	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	5	ment	ment	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	6	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	7	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	5	8	enjoyed	enjoy	VBD
work_xsvwzurwvngfnj4ubi324mvlje	5	9	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	10	most	most	JJS
work_xsvwzurwvngfnj4ubi324mvlje	5	11	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	5	12	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	5	13	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	14	primary	primary	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	15	focus	focus	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	16	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	17	my	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	5	18	commentary	commentary	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	19	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	5	20	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	5	21	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	22	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	23	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	24	sentence	sentence	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	25	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	26	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	27	discussion	discussion	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	28	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	5	29	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	5	30	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	5	31	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	5	32	an	an	DT
work_xsvwzurwvngfnj4ubi324mvlje	5	33	attractive	attractive	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	34	salvage	salvage	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	35	treatment	treatment	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	36	option	option	NN
work_xsvwzurwvngfnj4ubi324mvlje	5	37	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	38	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	5	39	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	5	40	persistent	persistent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	41	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	5	42	relapsed	relapse	VBN
work_xsvwzurwvngfnj4ubi324mvlje	5	43	hematologic	hematologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	44	malignancies	malignancy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	5	45	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	5	46	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	5	47	Attrac-	attrac-	WRB
work_xsvwzurwvngfnj4ubi324mvlje	5	48	tive	tive	JJ
work_xsvwzurwvngfnj4ubi324mvlje	5	49	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	6	1	Now	now	RB
work_xsvwzurwvngfnj4ubi324mvlje	6	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	6	3	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	6	4	may	may	MD
work_xsvwzurwvngfnj4ubi324mvlje	6	5	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	6	6	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	6	7	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	6	8	time	time	NN
work_xsvwzurwvngfnj4ubi324mvlje	6	9	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	6	10	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	6	11	heard	hear	VBN
work_xsvwzurwvngfnj4ubi324mvlje	6	12	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	6	13	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	6	14	being	be	VBG
work_xsvwzurwvngfnj4ubi324mvlje	6	15	described	describe	VBN
work_xsvwzurwvngfnj4ubi324mvlje	6	16	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	6	17	attractive	attractive	JJ
work_xsvwzurwvngfnj4ubi324mvlje	6	18	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	7	1	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	7	2	am	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	7	3	sure	sure	JJ
work_xsvwzurwvngfnj4ubi324mvlje	7	4	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	5	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	7	6	will	will	MD
work_xsvwzurwvngfnj4ubi324mvlje	7	7	hear	hear	VB
work_xsvwzurwvngfnj4ubi324mvlje	7	8	from	from	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	9	someone	someone	NN
work_xsvwzurwvngfnj4ubi324mvlje	7	10	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	11	far	far	RB
work_xsvwzurwvngfnj4ubi324mvlje	7	12	too	too	RB
work_xsvwzurwvngfnj4ubi324mvlje	7	13	much	much	JJ
work_xsvwzurwvngfnj4ubi324mvlje	7	14	time	time	NN
work_xsvwzurwvngfnj4ubi324mvlje	7	15	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	16	his	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	7	17	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	7	18	her	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	7	19	hands	hand	NNS
work_xsvwzurwvngfnj4ubi324mvlje	7	20	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	21	other	other	JJ
work_xsvwzurwvngfnj4ubi324mvlje	7	22	examples	example	NNS
work_xsvwzurwvngfnj4ubi324mvlje	7	23	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	7	24	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	7	25	adjective	adjective	NN
work_xsvwzurwvngfnj4ubi324mvlje	7	26	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	7	27	describe	describe	VB
work_xsvwzurwvngfnj4ubi324mvlje	7	28	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	7	29	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	7	30	but	but	CC
work_xsvwzurwvngfnj4ubi324mvlje	7	31	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	7	32	did	do	VBD
work_xsvwzurwvngfnj4ubi324mvlje	7	33	make	make	VB
work_xsvwzurwvngfnj4ubi324mvlje	7	34	me	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	7	35	take	take	VB
work_xsvwzurwvngfnj4ubi324mvlje	7	36	pause	pause	NN
work_xsvwzurwvngfnj4ubi324mvlje	7	37	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	8	1	Based	base	VBN
work_xsvwzurwvngfnj4ubi324mvlje	8	2	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	8	3	our	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	8	4	overall	overall	JJ
work_xsvwzurwvngfnj4ubi324mvlje	8	5	clinical	clinical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	8	6	experience	experience	NN
work_xsvwzurwvngfnj4ubi324mvlje	8	7	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	8	8	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	8	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	8	10	"	"	``
work_xsvwzurwvngfnj4ubi324mvlje	8	11	attractive	attractive	JJ
work_xsvwzurwvngfnj4ubi324mvlje	8	12	"	"	''
work_xsvwzurwvngfnj4ubi324mvlje	8	13	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	8	14	probably	probably	RB
work_xsvwzurwvngfnj4ubi324mvlje	8	15	one	one	CD
work_xsvwzurwvngfnj4ubi324mvlje	8	16	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	8	17	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	8	18	last	last	JJ
work_xsvwzurwvngfnj4ubi324mvlje	8	19	words	word	NNS
work_xsvwzurwvngfnj4ubi324mvlje	8	20	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	8	21	personally	personally	RB
work_xsvwzurwvngfnj4ubi324mvlje	8	22	would	would	MD
work_xsvwzurwvngfnj4ubi324mvlje	8	23	use	use	VB
work_xsvwzurwvngfnj4ubi324mvlje	8	24	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	8	25	describe	describe	VB
work_xsvwzurwvngfnj4ubi324mvlje	8	26	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	8	27	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	9	1	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	9	2	look	look	VBP
work_xsvwzurwvngfnj4ubi324mvlje	9	3	at	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	4	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	9	5	more	more	RBR
work_xsvwzurwvngfnj4ubi324mvlje	9	6	like	like	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	7	having	have	VBG
work_xsvwzurwvngfnj4ubi324mvlje	9	8	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	9	9	take	take	VB
work_xsvwzurwvngfnj4ubi324mvlje	9	10	your	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	9	11	best	good	JJS
work_xsvwzurwvngfnj4ubi324mvlje	9	12	friend	friend	NN
work_xsvwzurwvngfnj4ubi324mvlje	9	13	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	14	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	9	15	prom	prom	NN
work_xsvwzurwvngfnj4ubi324mvlje	9	16	because	because	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	17	neither	neither	DT
work_xsvwzurwvngfnj4ubi324mvlje	9	18	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	19	you	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	9	20	has	have	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	9	21	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	9	22	date	date	NN
work_xsvwzurwvngfnj4ubi324mvlje	9	23	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	9	24	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	9	25	neither	neither	DT
work_xsvwzurwvngfnj4ubi324mvlje	9	26	wants	want	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	9	27	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	9	28	go	go	VB
work_xsvwzurwvngfnj4ubi324mvlje	9	29	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	9	30	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	9	31	dance	dance	NN
work_xsvwzurwvngfnj4ubi324mvlje	9	32	alone	alone	RB
work_xsvwzurwvngfnj4ubi324mvlje	9	33	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	10	1	Out	out	IN
work_xsvwzurwvngfnj4ubi324mvlje	10	2	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	10	3	all	all	PDT
work_xsvwzurwvngfnj4ubi324mvlje	10	4	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	10	5	other	other	JJ
work_xsvwzurwvngfnj4ubi324mvlje	10	6	options	option	NNS
work_xsvwzurwvngfnj4ubi324mvlje	10	7	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	10	8	what	what	WP
work_xsvwzurwvngfnj4ubi324mvlje	10	9	do	do	VBP
work_xsvwzurwvngfnj4ubi324mvlje	10	10	you	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	10	11	do	do	VB
work_xsvwzurwvngfnj4ubi324mvlje	10	12	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	11	1	Beauty	beauty	NN
work_xsvwzurwvngfnj4ubi324mvlje	11	2	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	11	3	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	11	4	very	very	RB
work_xsvwzurwvngfnj4ubi324mvlje	11	5	relative	relative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	11	6	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	11	7	subjective	subjective	JJ
work_xsvwzurwvngfnj4ubi324mvlje	11	8	term	term	NN
work_xsvwzurwvngfnj4ubi324mvlje	11	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	11	10	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	11	11	maybe	maybe	RB
work_xsvwzurwvngfnj4ubi324mvlje	11	12	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	11	13	really	really	RB
work_xsvwzurwvngfnj4ubi324mvlje	11	14	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	11	15	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	11	16	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	11	17	eye	eye	NN
work_xsvwzurwvngfnj4ubi324mvlje	11	18	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	11	19	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	11	20	beholder	beholder	NN
work_xsvwzurwvngfnj4ubi324mvlje	11	21	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	12	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	12	2	report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	12	3	by	by	IN
work_xsvwzurwvngfnj4ubi324mvlje	12	4	Bar	Bar	NNP
work_xsvwzurwvngfnj4ubi324mvlje	12	5	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	12	6	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	12	7	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	13	1	provides	provide	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	13	2	wonderful	wonderful	JJ
work_xsvwzurwvngfnj4ubi324mvlje	13	3	background	background	NN
work_xsvwzurwvngfnj4ubi324mvlje	13	4	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	5	placing	place	VBG
work_xsvwzurwvngfnj4ubi324mvlje	13	6	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	13	7	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	13	8	beauty	beauty	NN
work_xsvwzurwvngfnj4ubi324mvlje	13	9	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	13	10	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	11	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	13	12	into	into	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	13	perspective	perspective	NN
work_xsvwzurwvngfnj4ubi324mvlje	13	14	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	13	15	reading	read	VBG
work_xsvwzurwvngfnj4ubi324mvlje	13	16	like	like	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	17	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	13	18	review	review	NN
work_xsvwzurwvngfnj4ubi324mvlje	13	19	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	20	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	13	21	history	history	NN
work_xsvwzurwvngfnj4ubi324mvlje	13	22	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	23	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	13	24	over	over	IN
work_xsvwzurwvngfnj4ubi324mvlje	13	25	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	13	26	past	past	JJ
work_xsvwzurwvngfnj4ubi324mvlje	13	27	23	23	CD
work_xsvwzurwvngfnj4ubi324mvlje	13	28	years	year	NNS
work_xsvwzurwvngfnj4ubi324mvlje	13	29	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	14	1	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	14	2	would	would	MD
work_xsvwzurwvngfnj4ubi324mvlje	14	3	actually	actually	RB
work_xsvwzurwvngfnj4ubi324mvlje	14	4	argue	argue	VB
work_xsvwzurwvngfnj4ubi324mvlje	14	5	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	14	6	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	14	7	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	14	8	report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	14	9	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	14	10	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	14	11	required	require	VBN
work_xsvwzurwvngfnj4ubi324mvlje	14	12	reading	read	VBG
work_xsvwzurwvngfnj4ubi324mvlje	14	13	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	14	14	fellows	fellow	NNS
work_xsvwzurwvngfnj4ubi324mvlje	14	15	during	during	IN
work_xsvwzurwvngfnj4ubi324mvlje	14	16	their	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	14	17	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	14	18	rotation	rotation	NN
work_xsvwzurwvngfnj4ubi324mvlje	14	19	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	14	20	an	an	DT
work_xsvwzurwvngfnj4ubi324mvlje	14	21	excellent	excellent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	14	22	journal	journal	NNP
work_xsvwzurwvngfnj4ubi324mvlje	14	23	club	club	NN
work_xsvwzurwvngfnj4ubi324mvlje	14	24	article	article	NN
work_xsvwzurwvngfnj4ubi324mvlje	14	25	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	15	1	It	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	15	2	starts	start	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	15	3	out	out	RP
work_xsvwzurwvngfnj4ubi324mvlje	15	4	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	5	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	15	6	obligatory	obligatory	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	7	statement	statement	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	8	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	9	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	15	10	Allogeneic	Allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	15	11	hematopoietic	hematopoietic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	12	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	13	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	14	has	have	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	15	15	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	15	16	potential	potential	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	17	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	15	18	provide	provide	VB
work_xsvwzurwvngfnj4ubi324mvlje	15	19	long	long	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	20	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	15	21	term	term	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	22	survival	survival	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	23	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	15	24	even	even	RB
work_xsvwzurwvngfnj4ubi324mvlje	15	25	cure	cure	VB
work_xsvwzurwvngfnj4ubi324mvlje	15	26	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	27	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	15	28	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	29	hematologic	hematologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	30	malig-	malig-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	15	31	nancies	nancy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	15	32	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	15	33	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	15	34	which	which	WDT
work_xsvwzurwvngfnj4ubi324mvlje	15	35	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	15	36	tough	tough	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	37	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	15	38	argue	argue	VB
work_xsvwzurwvngfnj4ubi324mvlje	15	39	considering	consider	VBG
work_xsvwzurwvngfnj4ubi324mvlje	15	40	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	41	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	15	42	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	15	43	started	start	VBN
work_xsvwzurwvngfnj4ubi324mvlje	15	44	approximately	approximately	RB
work_xsvwzurwvngfnj4ubi324mvlje	15	45	one	one	CD
work_xsvwzurwvngfnj4ubi324mvlje	15	46	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	15	47	half	half	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	48	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	49	my	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	15	50	own	own	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	51	publications	publication	NNS
work_xsvwzurwvngfnj4ubi324mvlje	15	52	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	15	53	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	15	54	same	same	JJ
work_xsvwzurwvngfnj4ubi324mvlje	15	55	statement	statement	NN
work_xsvwzurwvngfnj4ubi324mvlje	15	56	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	16	1	This	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	2	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	16	3	followed	follow	VBN
work_xsvwzurwvngfnj4ubi324mvlje	16	4	by	by	IN
work_xsvwzurwvngfnj4ubi324mvlje	16	5	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	6	statement	statement	NN
work_xsvwzurwvngfnj4ubi324mvlje	16	7	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	16	8	who	who	WP
work_xsvwzurwvngfnj4ubi324mvlje	16	9	reported	report	VBD
work_xsvwzurwvngfnj4ubi324mvlje	16	10	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	11	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	16	12	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	16	13	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	16	14	which	which	WDT
work_xsvwzurwvngfnj4ubi324mvlje	16	15	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	16	16	where	where	WRB
work_xsvwzurwvngfnj4ubi324mvlje	16	17	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	16	18	really	really	RB
work_xsvwzurwvngfnj4ubi324mvlje	16	19	starts	start	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	16	20	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	16	21	get	get	VB
work_xsvwzurwvngfnj4ubi324mvlje	16	22	interesting	interesting	JJ
work_xsvwzurwvngfnj4ubi324mvlje	16	23	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	16	24	given	give	VBN
work_xsvwzurwvngfnj4ubi324mvlje	16	25	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	16	26	even	even	RB
work_xsvwzurwvngfnj4ubi324mvlje	16	27	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	28	little	little	JJ
work_xsvwzurwvngfnj4ubi324mvlje	16	29	3-patient	3-patient	CD
work_xsvwzurwvngfnj4ubi324mvlje	16	30	report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	16	31	has	have	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	16	32	been	be	VBN
work_xsvwzurwvngfnj4ubi324mvlje	16	33	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	34	repeated	repeat	VBN
work_xsvwzurwvngfnj4ubi324mvlje	16	35	point	point	NN
work_xsvwzurwvngfnj4ubi324mvlje	16	36	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	16	37	contention	contention	NN
work_xsvwzurwvngfnj4ubi324mvlje	16	38	over	over	IN
work_xsvwzurwvngfnj4ubi324mvlje	16	39	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	16	40	years	year	NNS
work_xsvwzurwvngfnj4ubi324mvlje	16	41	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	16	42	2,3	2,3	CD
work_xsvwzurwvngfnj4ubi324mvlje	16	43	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	16	44	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	17	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	17	2	article	article	NN
work_xsvwzurwvngfnj4ubi324mvlje	17	3	then	then	RB
work_xsvwzurwvngfnj4ubi324mvlje	17	4	moves	move	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	17	5	on	on	RP
work_xsvwzurwvngfnj4ubi324mvlje	17	6	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	17	7	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	17	8	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	17	9	Patients	Patients	NNPS
work_xsvwzurwvngfnj4ubi324mvlje	17	10	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	17	11	Methods	Methods	NNPS
work_xsvwzurwvngfnj4ubi324mvlje	17	12	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	17	13	section	section	NN
work_xsvwzurwvngfnj4ubi324mvlje	17	14	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	17	15	describe	describe	VB
work_xsvwzurwvngfnj4ubi324mvlje	17	16	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	17	17	225	225	CD
work_xsvwzurwvngfnj4ubi324mvlje	17	18	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	17	19	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	17	20	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	17	21	broad	broad	JJ
work_xsvwzurwvngfnj4ubi324mvlje	17	22	variety	variety	NN
work_xsvwzurwvngfnj4ubi324mvlje	17	23	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	17	24	hematologic	hematologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	17	25	malignancies	malignancy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	17	26	who	who	WP
work_xsvwzurwvngfnj4ubi324mvlje	17	27	were	be	VBD
work_xsvwzurwvngfnj4ubi324mvlje	17	28	treated	treat	VBN
work_xsvwzurwvngfnj4ubi324mvlje	17	29	over	over	IN
work_xsvwzurwvngfnj4ubi324mvlje	17	30	an	an	DT
work_xsvwzurwvngfnj4ubi324mvlje	17	31	18-year	18-year	CD
work_xsvwzurwvngfnj4ubi324mvlje	17	32	Financial	financial	JJ
work_xsvwzurwvngfnj4ubi324mvlje	17	33	disclosure	disclosure	NN
work_xsvwzurwvngfnj4ubi324mvlje	17	34	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	17	35	See	see	VB
work_xsvwzurwvngfnj4ubi324mvlje	17	36	Acknowledgments	acknowledgment	NNS
work_xsvwzurwvngfnj4ubi324mvlje	17	37	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	17	38	page	page	NN
work_xsvwzurwvngfnj4ubi324mvlje	17	39	850	850	CD
work_xsvwzurwvngfnj4ubi324mvlje	17	40	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	18	1	*	*	NFP
work_xsvwzurwvngfnj4ubi324mvlje	18	2	Correspondence	correspondence	NN
work_xsvwzurwvngfnj4ubi324mvlje	18	3	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	18	4	reprint	reprint	NN
work_xsvwzurwvngfnj4ubi324mvlje	18	5	requests	request	NNS
work_xsvwzurwvngfnj4ubi324mvlje	18	6	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	18	7	Michael	Michael	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	8	R.	R.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	9	Bishop	Bishop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	11	MD	MD	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	12	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	13	Section	Section	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	14	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	18	15	Hematology	Hematology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	16	/	/	SYM
work_xsvwzurwvngfnj4ubi324mvlje	18	17	Oncology	Oncology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	18	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	19	University	University	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	20	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	18	21	Chicago	Chicago	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	22	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	23	5841	5841	CD
work_xsvwzurwvngfnj4ubi324mvlje	18	24	South	South	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	25	Maryland	Maryland	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	26	Ave	Ave	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	27	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	28	MC	MC	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	29	2115	2115	CD
work_xsvwzurwvngfnj4ubi324mvlje	18	30	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	31	Chicago	Chicago	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	32	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	18	33	IL	IL	NNP
work_xsvwzurwvngfnj4ubi324mvlje	18	34	60637	60637	CD
work_xsvwzurwvngfnj4ubi324mvlje	18	35	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	19	1	E	e	NN
work_xsvwzurwvngfnj4ubi324mvlje	19	2	-	-	NN
work_xsvwzurwvngfnj4ubi324mvlje	19	3	mail	mail	NN
work_xsvwzurwvngfnj4ubi324mvlje	19	4	address	address	NN
work_xsvwzurwvngfnj4ubi324mvlje	19	5	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	19	6	mbishop@medicine.bsd.uchicago.edu	mbishop@medicine.bsd.uchicago.edu	ADD
work_xsvwzurwvngfnj4ubi324mvlje	19	7	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	20	1	1083	1083	CD
work_xsvwzurwvngfnj4ubi324mvlje	20	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	20	3	8791/$	8791/$	CD
work_xsvwzurwvngfnj4ubi324mvlje	20	4	e	e	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	5	see	see	VB
work_xsvwzurwvngfnj4ubi324mvlje	20	6	front	front	JJ
work_xsvwzurwvngfnj4ubi324mvlje	20	7	matter	matter	NN
work_xsvwzurwvngfnj4ubi324mvlje	20	8	�	�	.
work_xsvwzurwvngfnj4ubi324mvlje	20	9	2013	2013	CD
work_xsvwzurwvngfnj4ubi324mvlje	20	10	American	American	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	11	Society	Society	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	12	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	20	13	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	14	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	20	15	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	16	Transplantation	Transplantation	NNP
work_xsvwzurwvngfnj4ubi324mvlje	20	17	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	21	1	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	2	period	period	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	4	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	5	then	then	RB
work_xsvwzurwvngfnj4ubi324mvlje	21	6	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	7	how	how	WRB
work_xsvwzurwvngfnj4ubi324mvlje	21	8	specifically	specifically	RB
work_xsvwzurwvngfnj4ubi324mvlje	21	9	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	10	was	be	VBD
work_xsvwzurwvngfnj4ubi324mvlje	21	11	used	use	VBN
work_xsvwzurwvngfnj4ubi324mvlje	21	12	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	21	13	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	14	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	15	without	without	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	16	chemotherapy	chemotherapy	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	17	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	18	radiation	radiation	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	19	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	20	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	21	adjuvant	adjuvant	JJ
work_xsvwzurwvngfnj4ubi324mvlje	21	22	cytokines	cytokine	NNS
work_xsvwzurwvngfnj4ubi324mvlje	21	23	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	21	24	eg	eg	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	25	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	26	IFN	IFN	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	27	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	28	IL-2	IL-2	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	29	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	21	30	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	31	use	use	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	32	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	33	steady	steady	JJ
work_xsvwzurwvngfnj4ubi324mvlje	21	34	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	21	35	state	state	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	36	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	37	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	21	38	mobilized	mobilize	VBN
work_xsvwzurwvngfnj4ubi324mvlje	21	39	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	21	40	DLI	dli	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	41	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	42	chimerism	chimerism	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	43	status	status	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	44	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	45	presence	presence	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	46	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	47	absence	absence	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	48	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	49	GVHD	GVHD	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	50	at	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	51	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	21	52	time	time	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	53	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	54	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	55	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	21	56	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	21	57	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	21	58	use	use	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	59	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	21	60	immunosuppression	immunosuppression	NN
work_xsvwzurwvngfnj4ubi324mvlje	21	61	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	21	62	prevent	prevent	VB
work_xsvwzurwvngfnj4ubi324mvlje	21	63	GVHD	GVHD	NNP
work_xsvwzurwvngfnj4ubi324mvlje	21	64	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	22	1	Sound	sound	VB
work_xsvwzurwvngfnj4ubi324mvlje	22	2	familiar	familiar	JJ
work_xsvwzurwvngfnj4ubi324mvlje	22	3	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	23	1	This	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	23	2	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	23	3	not	not	RB
work_xsvwzurwvngfnj4ubi324mvlje	23	4	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	23	5	criticismdthese	criticismdthese	NNS
work_xsvwzurwvngfnj4ubi324mvlje	23	6	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	23	7	extremely	extremely	RB
work_xsvwzurwvngfnj4ubi324mvlje	23	8	relevant	relevant	JJ
work_xsvwzurwvngfnj4ubi324mvlje	23	9	biologic	biologic	NN
work_xsvwzurwvngfnj4ubi324mvlje	23	10	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	23	11	clinical	clinical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	23	12	issues	issue	NNS
work_xsvwzurwvngfnj4ubi324mvlje	23	13	that	that	WDT
work_xsvwzurwvngfnj4ubi324mvlje	23	14	investigators	investigator	NNS
work_xsvwzurwvngfnj4ubi324mvlje	23	15	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	23	16	attempted	attempt	VBN
work_xsvwzurwvngfnj4ubi324mvlje	23	17	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	23	18	address	address	VB
work_xsvwzurwvngfnj4ubi324mvlje	23	19	over	over	IN
work_xsvwzurwvngfnj4ubi324mvlje	23	20	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	23	21	past	past	JJ
work_xsvwzurwvngfnj4ubi324mvlje	23	22	20	20	CD
work_xsvwzurwvngfnj4ubi324mvlje	23	23	years	year	NNS
work_xsvwzurwvngfnj4ubi324mvlje	23	24	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	23	25	4	4	CD
work_xsvwzurwvngfnj4ubi324mvlje	23	26	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	23	27	7	7	CD
work_xsvwzurwvngfnj4ubi324mvlje	23	28	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	23	29	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	24	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	24	2	authors	author	NNS
work_xsvwzurwvngfnj4ubi324mvlje	24	3	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	24	4	self	self	NN
work_xsvwzurwvngfnj4ubi324mvlje	24	5	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	24	6	depreciating	depreciate	VBG
work_xsvwzurwvngfnj4ubi324mvlje	24	7	when	when	WRB
work_xsvwzurwvngfnj4ubi324mvlje	24	8	describing	describe	VBG
work_xsvwzurwvngfnj4ubi324mvlje	24	9	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	24	10	heterogeneity	heterogeneity	NN
work_xsvwzurwvngfnj4ubi324mvlje	24	11	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	24	12	their	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	24	13	patient	patient	JJ
work_xsvwzurwvngfnj4ubi324mvlje	24	14	populations	population	NNS
work_xsvwzurwvngfnj4ubi324mvlje	24	15	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	24	16	treatment	treatment	NN
work_xsvwzurwvngfnj4ubi324mvlje	24	17	approaches	approach	NNS
work_xsvwzurwvngfnj4ubi324mvlje	24	18	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	24	19	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	24	20	limitation	limitation	NN
work_xsvwzurwvngfnj4ubi324mvlje	24	21	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	24	22	their	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	24	23	study	study	NN
work_xsvwzurwvngfnj4ubi324mvlje	24	24	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	25	1	However	however	RB
work_xsvwzurwvngfnj4ubi324mvlje	25	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	25	3	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	25	4	look	look	VBP
work_xsvwzurwvngfnj4ubi324mvlje	25	5	at	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	6	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	7	heterogeneity	heterogeneity	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	8	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	9	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	10	strength	strength	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	11	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	25	12	placing	place	VBG
work_xsvwzurwvngfnj4ubi324mvlje	25	13	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	14	use	use	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	15	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	16	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	25	17	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	18	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	19	compact	compact	JJ
work_xsvwzurwvngfnj4ubi324mvlje	25	20	historical	historical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	25	21	framework	framework	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	22	by	by	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	23	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	24	group	group	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	25	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	26	investigators	investigator	NNS
work_xsvwzurwvngfnj4ubi324mvlje	25	27	who	who	WP
work_xsvwzurwvngfnj4ubi324mvlje	25	28	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	25	29	been	be	VBN
work_xsvwzurwvngfnj4ubi324mvlje	25	30	at	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	31	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	25	32	forefront	forefront	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	33	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	34	translational	translational	JJ
work_xsvwzurwvngfnj4ubi324mvlje	25	35	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	25	36	clinical	clinical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	25	37	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	38	research	research	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	39	since	since	IN
work_xsvwzurwvngfnj4ubi324mvlje	25	40	its	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	25	41	inception	inception	NN
work_xsvwzurwvngfnj4ubi324mvlje	25	42	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	26	1	Possibly	possibly	RB
work_xsvwzurwvngfnj4ubi324mvlje	26	2	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	26	3	most	most	RBS
work_xsvwzurwvngfnj4ubi324mvlje	26	4	informative	informative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	26	5	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	26	6	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	26	7	somewhat	somewhat	RB
work_xsvwzurwvngfnj4ubi324mvlje	26	8	comforting	comforting	JJ
work_xsvwzurwvngfnj4ubi324mvlje	26	9	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	26	10	aspect	aspect	NN
work_xsvwzurwvngfnj4ubi324mvlje	26	11	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	26	12	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	26	13	report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	26	14	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	26	15	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	26	16	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	26	17	authors	author	NNS
work_xsvwzurwvngfnj4ubi324mvlje	26	18	’	’	POS
work_xsvwzurwvngfnj4ubi324mvlje	26	19	results	result	NNS
work_xsvwzurwvngfnj4ubi324mvlje	26	20	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	26	21	very	very	RB
work_xsvwzurwvngfnj4ubi324mvlje	26	22	similar	similar	JJ
work_xsvwzurwvngfnj4ubi324mvlje	26	23	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	26	24	what	what	WP
work_xsvwzurwvngfnj4ubi324mvlje	26	25	has	have	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	26	26	been	be	VBN
work_xsvwzurwvngfnj4ubi324mvlje	26	27	previously	previously	RB
work_xsvwzurwvngfnj4ubi324mvlje	26	28	reported	report	VBN
work_xsvwzurwvngfnj4ubi324mvlje	26	29	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	26	30	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	26	31	general	general	JJ
work_xsvwzurwvngfnj4ubi324mvlje	26	32	perceptions	perception	NNS
work_xsvwzurwvngfnj4ubi324mvlje	26	33	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	26	34	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	26	35	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	26	36	community	community	NN
work_xsvwzurwvngfnj4ubi324mvlje	26	37	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	26	38	8,9	8,9	CD
work_xsvwzurwvngfnj4ubi324mvlje	26	39	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	26	40	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	27	1	Consistent	consistent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	27	2	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	27	3	previous	previous	JJ
work_xsvwzurwvngfnj4ubi324mvlje	27	4	observations	observation	NNS
work_xsvwzurwvngfnj4ubi324mvlje	27	5	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	27	6	Bar	Bar	NNP
work_xsvwzurwvngfnj4ubi324mvlje	27	7	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	27	8	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	27	9	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	28	1	found	find	VBN
work_xsvwzurwvngfnj4ubi324mvlje	28	2	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	3	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	28	4	dose	dose	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	5	was	be	VBD
work_xsvwzurwvngfnj4ubi324mvlje	28	6	correlated	correlate	VBN
work_xsvwzurwvngfnj4ubi324mvlje	28	7	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	8	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	28	9	risk	risk	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	10	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	11	GVHD	GVHD	NNP
work_xsvwzurwvngfnj4ubi324mvlje	28	12	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	28	13	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	28	14	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	15	higher	high	JJR
work_xsvwzurwvngfnj4ubi324mvlje	28	16	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	28	17	doses	dose	NNS
work_xsvwzurwvngfnj4ubi324mvlje	28	18	did	do	VBD
work_xsvwzurwvngfnj4ubi324mvlje	28	19	not	not	RB
work_xsvwzurwvngfnj4ubi324mvlje	28	20	decrease	decrease	VB
work_xsvwzurwvngfnj4ubi324mvlje	28	21	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	28	22	risk	risk	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	23	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	24	recurrence	recurrence	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	25	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	28	26	successful	successful	JJ
work_xsvwzurwvngfnj4ubi324mvlje	28	27	DLI	dli	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	28	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	28	29	improve	improve	VB
work_xsvwzurwvngfnj4ubi324mvlje	28	30	overall	overall	JJ
work_xsvwzurwvngfnj4ubi324mvlje	28	31	survival	survival	NN
work_xsvwzurwvngfnj4ubi324mvlje	28	32	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	29	1	At	at	IN
work_xsvwzurwvngfnj4ubi324mvlje	29	2	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	29	3	same	same	JJ
work_xsvwzurwvngfnj4ubi324mvlje	29	4	time	time	NN
work_xsvwzurwvngfnj4ubi324mvlje	29	5	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	29	6	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	29	7	results	result	NNS
work_xsvwzurwvngfnj4ubi324mvlje	29	8	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	29	9	very	very	RB
work_xsvwzurwvngfnj4ubi324mvlje	29	10	disappointing	disappointing	JJ
work_xsvwzurwvngfnj4ubi324mvlje	29	11	relative	relative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	29	12	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	29	13	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	29	14	lack	lack	NN
work_xsvwzurwvngfnj4ubi324mvlje	29	15	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	29	16	progress	progress	NN
work_xsvwzurwvngfnj4ubi324mvlje	29	17	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	29	18	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	29	19	over	over	IN
work_xsvwzurwvngfnj4ubi324mvlje	29	20	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	29	21	last	last	JJ
work_xsvwzurwvngfnj4ubi324mvlje	29	22	25	25	CD
work_xsvwzurwvngfnj4ubi324mvlje	29	23	years	year	NNS
work_xsvwzurwvngfnj4ubi324mvlje	29	24	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	30	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	30	2	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	30	3	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	30	4	which	which	WDT
work_xsvwzurwvngfnj4ubi324mvlje	30	5	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	30	6	has	have	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	30	7	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	30	8	best	good	JJS
work_xsvwzurwvngfnj4ubi324mvlje	30	9	results	result	NNS
work_xsvwzurwvngfnj4ubi324mvlje	30	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	30	11	chronic	chronic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	30	12	myelogenous	myelogenous	JJ
work_xsvwzurwvngfnj4ubi324mvlje	30	13	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	30	14	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	30	15	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	30	16	today	today	NN
work_xsvwzurwvngfnj4ubi324mvlje	30	17	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	30	18	relatively	relatively	RB
work_xsvwzurwvngfnj4ubi324mvlje	30	19	rare	rare	JJ
work_xsvwzurwvngfnj4ubi324mvlje	30	20	indication	indication	NN
work_xsvwzurwvngfnj4ubi324mvlje	30	21	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	30	22	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	30	23	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	31	1	We	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	31	2	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	31	3	still	still	RB
work_xsvwzurwvngfnj4ubi324mvlje	31	4	unsure	unsure	JJ
work_xsvwzurwvngfnj4ubi324mvlje	31	5	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	31	6	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	31	7	exactly	exactly	RB
work_xsvwzurwvngfnj4ubi324mvlje	31	8	when	when	WRB
work_xsvwzurwvngfnj4ubi324mvlje	31	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	31	10	how	how	WRB
work_xsvwzurwvngfnj4ubi324mvlje	31	11	often	often	RB
work_xsvwzurwvngfnj4ubi324mvlje	31	12	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	31	13	how	how	WRB
work_xsvwzurwvngfnj4ubi324mvlje	31	14	much	much	RB
work_xsvwzurwvngfnj4ubi324mvlje	31	15	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	31	16	precisely	precisely	RB
work_xsvwzurwvngfnj4ubi324mvlje	31	17	what	what	WP
work_xsvwzurwvngfnj4ubi324mvlje	31	18	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	31	19	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	31	20	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	31	21	what	what	WP
work_xsvwzurwvngfnj4ubi324mvlje	31	22	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	31	23	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	31	24	use	use	VB
work_xsvwzurwvngfnj4ubi324mvlje	31	25	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	31	26	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	32	1	Relative	relative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	32	2	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	3	when	when	WRB
work_xsvwzurwvngfnj4ubi324mvlje	32	4	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	32	5	there	there	EX
work_xsvwzurwvngfnj4ubi324mvlje	32	6	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	32	7	no	no	DT
work_xsvwzurwvngfnj4ubi324mvlje	32	8	established	established	JJ
work_xsvwzurwvngfnj4ubi324mvlje	32	9	methods	method	NNS
work_xsvwzurwvngfnj4ubi324mvlje	32	10	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	32	11	guidelines	guideline	NNS
work_xsvwzurwvngfnj4ubi324mvlje	32	12	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	13	monitoring	monitor	VBG
work_xsvwzurwvngfnj4ubi324mvlje	32	14	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	15	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	32	16	recurrence	recurrence	NN
work_xsvwzurwvngfnj4ubi324mvlje	32	17	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	18	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	32	19	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	32	20	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	21	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	32	22	possible	possible	JJ
work_xsvwzurwvngfnj4ubi324mvlje	32	23	exception	exception	NN
work_xsvwzurwvngfnj4ubi324mvlje	32	24	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	32	25	chronic	chronic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	32	26	myelogeous	myelogeous	JJ
work_xsvwzurwvngfnj4ubi324mvlje	32	27	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	32	28	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	33	1	Bar	bar	VB
work_xsvwzurwvngfnj4ubi324mvlje	33	2	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	33	3	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	33	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	34	1	addressed	address	VBN
work_xsvwzurwvngfnj4ubi324mvlje	34	2	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	34	3	dose	dose	VB
work_xsvwzurwvngfnj4ubi324mvlje	34	4	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	34	5	but	but	CC
work_xsvwzurwvngfnj4ubi324mvlje	34	6	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	34	7	optimal	optimal	JJ
work_xsvwzurwvngfnj4ubi324mvlje	34	8	starting	starting	NN
work_xsvwzurwvngfnj4ubi324mvlje	34	9	dose	dose	RB
work_xsvwzurwvngfnj4ubi324mvlje	34	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	34	11	whether	whether	IN
work_xsvwzurwvngfnj4ubi324mvlje	34	12	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	34	13	doses	dose	NNS
work_xsvwzurwvngfnj4ubi324mvlje	34	14	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	34	15	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	34	16	escalated	escalate	VBN
work_xsvwzurwvngfnj4ubi324mvlje	34	17	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	34	18	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	34	19	if	if	IN
work_xsvwzurwvngfnj4ubi324mvlje	34	20	so	so	RB
work_xsvwzurwvngfnj4ubi324mvlje	34	21	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	34	22	how	how	WRB
work_xsvwzurwvngfnj4ubi324mvlje	34	23	often	often	RB
work_xsvwzurwvngfnj4ubi324mvlje	34	24	remain	remain	VBP
work_xsvwzurwvngfnj4ubi324mvlje	34	25	unclear	unclear	JJ
work_xsvwzurwvngfnj4ubi324mvlje	34	26	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	35	1	Maybe	maybe	RB
work_xsvwzurwvngfnj4ubi324mvlje	35	2	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	35	3	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	35	4	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	35	5	giving	give	VBG
work_xsvwzurwvngfnj4ubi324mvlje	35	6	relatively	relatively	RB
work_xsvwzurwvngfnj4ubi324mvlje	35	7	small	small	JJ
work_xsvwzurwvngfnj4ubi324mvlje	35	8	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	35	9	<	<	XX
work_xsvwzurwvngfnj4ubi324mvlje	35	10	1	1	CD
work_xsvwzurwvngfnj4ubi324mvlje	35	11	�	�	NNP
work_xsvwzurwvngfnj4ubi324mvlje	35	12	106	106	CD
work_xsvwzurwvngfnj4ubi324mvlje	35	13	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	35	14	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	35	15	/	/	SYM
work_xsvwzurwvngfnj4ubi324mvlje	35	16	kg	kg	NNS
work_xsvwzurwvngfnj4ubi324mvlje	35	17	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	35	18	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	35	19	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	35	20	more	more	RBR
work_xsvwzurwvngfnj4ubi324mvlje	35	21	frequent	frequent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	35	22	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	35	23	weekly	weekly	JJ
work_xsvwzurwvngfnj4ubi324mvlje	35	24	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	35	25	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	36	1	basis	basis	NN
work_xsvwzurwvngfnj4ubi324mvlje	36	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	37	1	Other	other	JJ
work_xsvwzurwvngfnj4ubi324mvlje	37	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	37	3	possibly	possibly	RB
work_xsvwzurwvngfnj4ubi324mvlje	37	4	even	even	RB
work_xsvwzurwvngfnj4ubi324mvlje	37	5	more	more	RBR
work_xsvwzurwvngfnj4ubi324mvlje	37	6	important	important	JJ
work_xsvwzurwvngfnj4ubi324mvlje	37	7	questions	question	NNS
work_xsvwzurwvngfnj4ubi324mvlje	37	8	involve	involve	VBP
work_xsvwzurwvngfnj4ubi324mvlje	37	9	product	product	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	10	content	content	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	11	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	37	12	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	37	13	need	need	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	14	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	37	15	cytoreduction	cytoreduction	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	16	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	37	17	achieve	achieve	VB
work_xsvwzurwvngfnj4ubi324mvlje	37	18	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	37	19	minimal	minimal	JJ
work_xsvwzurwvngfnj4ubi324mvlje	37	20	residual	residual	JJ
work_xsvwzurwvngfnj4ubi324mvlje	37	21	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	22	state	state	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	23	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	37	24	immunodepletion	immunodepletion	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	25	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	37	26	creation	creation	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	27	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	37	28	immu-	immu-	FW
work_xsvwzurwvngfnj4ubi324mvlje	37	29	nologic	nologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	37	30	“	"	``
work_xsvwzurwvngfnj4ubi324mvlje	37	31	space	space	NN
work_xsvwzurwvngfnj4ubi324mvlje	37	32	”	"	''
work_xsvwzurwvngfnj4ubi324mvlje	37	33	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	37	34	10	10	CD
work_xsvwzurwvngfnj4ubi324mvlje	37	35	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	37	36	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	38	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	38	2	correlation	correlation	NN
work_xsvwzurwvngfnj4ubi324mvlje	38	3	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	4	success	success	NN
work_xsvwzurwvngfnj4ubi324mvlje	38	5	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	6	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	38	7	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	8	minimal	minimal	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	9	residual	residual	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	10	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	38	11	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	38	12	well	well	RB
work_xsvwzurwvngfnj4ubi324mvlje	38	13	established	establish	VBN
work_xsvwzurwvngfnj4ubi324mvlje	38	14	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	38	15	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	38	16	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	38	17	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	38	18	difficult	difficult	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	19	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	38	20	expect	expect	VB
work_xsvwzurwvngfnj4ubi324mvlje	38	21	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	38	22	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	38	23	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	38	24	successful	successful	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	25	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	26	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	38	27	context	context	NN
work_xsvwzurwvngfnj4ubi324mvlje	38	28	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	29	competing	compete	VBG
work_xsvwzurwvngfnj4ubi324mvlje	38	30	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	31	homeostatic	homeostatic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	32	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	38	33	stimulatory	stimulatory	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	34	cytokines	cytokine	NNS
work_xsvwzurwvngfnj4ubi324mvlje	38	35	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	36	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	38	37	immunologically	immunologically	RB
work_xsvwzurwvngfnj4ubi324mvlje	38	38	competent	competent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	39	host	host	NN
work_xsvwzurwvngfnj4ubi324mvlje	38	40	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	38	41	potentially	potentially	RB
work_xsvwzurwvngfnj4ubi324mvlje	38	42	inhibitory	inhibitory	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	43	features	feature	NNS
work_xsvwzurwvngfnj4ubi324mvlje	38	44	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	38	45	eg	eg	NNP
work_xsvwzurwvngfnj4ubi324mvlje	38	46	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	38	47	T	T	NNP
work_xsvwzurwvngfnj4ubi324mvlje	38	48	regulatory	regulatory	JJ
work_xsvwzurwvngfnj4ubi324mvlje	38	49	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	38	50	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	38	51	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	39	1	Relative	relative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	39	2	to	to	IN
work_xsvwzurwvngfnj4ubi324mvlje	39	3	content	content	NN
work_xsvwzurwvngfnj4ubi324mvlje	39	4	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	39	5	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	39	6	they	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	39	7	specifi-	specifi-	XX
work_xsvwzurwvngfnj4ubi324mvlje	39	8	cally	cally	RB
work_xsvwzurwvngfnj4ubi324mvlje	39	9	be	be	VB
work_xsvwzurwvngfnj4ubi324mvlje	39	10	just	just	RB
work_xsvwzurwvngfnj4ubi324mvlje	39	11	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	39	12	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	39	13	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	39	14	subsets	subset	NNS
work_xsvwzurwvngfnj4ubi324mvlje	39	15	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	39	16	natural	natural	JJ
work_xsvwzurwvngfnj4ubi324mvlje	39	17	killer	killer	NN
work_xsvwzurwvngfnj4ubi324mvlje	39	18	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	39	19	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	39	20	or	or	CC
work_xsvwzurwvngfnj4ubi324mvlje	39	21	some	some	DT
work_xsvwzurwvngfnj4ubi324mvlje	39	22	combination	combination	NN
work_xsvwzurwvngfnj4ubi324mvlje	39	23	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	40	1	Finally	finally	RB
work_xsvwzurwvngfnj4ubi324mvlje	40	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	40	3	should	should	MD
work_xsvwzurwvngfnj4ubi324mvlje	40	4	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	40	5	just	just	RB
work_xsvwzurwvngfnj4ubi324mvlje	40	6	accept	accept	VB
work_xsvwzurwvngfnj4ubi324mvlje	40	7	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	40	8	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	40	9	fact	fact	NN
work_xsvwzurwvngfnj4ubi324mvlje	40	10	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	40	11	no	no	RB
work_xsvwzurwvngfnj4ubi324mvlje	40	12	matter	matter	RB
work_xsvwzurwvngfnj4ubi324mvlje	40	13	what	what	WP
work_xsvwzurwvngfnj4ubi324mvlje	40	14	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	40	15	attempt	attempt	VBP
work_xsvwzurwvngfnj4ubi324mvlje	40	16	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	40	17	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	40	18	results	result	NNS
work_xsvwzurwvngfnj4ubi324mvlje	40	19	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	40	20	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	40	21	will	will	MD
work_xsvwzurwvngfnj4ubi324mvlje	40	22	end	end	VB
work_xsvwzurwvngfnj4ubi324mvlje	40	23	up	up	RP
work_xsvwzurwvngfnj4ubi324mvlje	40	24	being	be	VBG
work_xsvwzurwvngfnj4ubi324mvlje	40	25	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	40	26	same	same	JJ
work_xsvwzurwvngfnj4ubi324mvlje	40	27	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	41	1	It	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	41	2	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	41	3	my	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	41	4	strong	strong	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	5	belief	belief	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	6	this	this	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	7	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	41	8	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	9	not	not	RB
work_xsvwzurwvngfnj4ubi324mvlje	41	10	case	case	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	11	;	;	:
work_xsvwzurwvngfnj4ubi324mvlje	41	12	many	many	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	13	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	41	14	these	these	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	15	questions	question	NNS
work_xsvwzurwvngfnj4ubi324mvlje	41	16	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	41	17	been	be	VBN
work_xsvwzurwvngfnj4ubi324mvlje	41	18	only	only	RB
work_xsvwzurwvngfnj4ubi324mvlje	41	19	partially	partially	RB
work_xsvwzurwvngfnj4ubi324mvlje	41	20	addressed	address	VBN
work_xsvwzurwvngfnj4ubi324mvlje	41	21	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	41	22	an	an	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	23	adequate	adequate	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	24	manner	manner	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	25	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	41	26	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	41	27	there	there	EX
work_xsvwzurwvngfnj4ubi324mvlje	41	28	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	41	29	several	several	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	30	new	new	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	31	modalities	modality	NNS
work_xsvwzurwvngfnj4ubi324mvlje	41	32	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	41	33	such	such	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	34	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	41	35	chi-	chi-	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	36	meric	meric	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	37	antigen	antigen	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	38	receptors	receptor	NNS
work_xsvwzurwvngfnj4ubi324mvlje	41	39	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	41	40	that	that	WDT
work_xsvwzurwvngfnj4ubi324mvlje	41	41	may	may	MD
work_xsvwzurwvngfnj4ubi324mvlje	41	42	enhance	enhance	VB
work_xsvwzurwvngfnj4ubi324mvlje	41	43	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	44	efficacy	efficacy	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	45	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	41	46	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	47	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	41	48	merit	merit	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	49	further	further	JJ
work_xsvwzurwvngfnj4ubi324mvlje	41	50	investigation	investigation	NN
work_xsvwzurwvngfnj4ubi324mvlje	41	51	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	41	52	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	41	53	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	54	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	55	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	http://dx.doi.org/10.1016/j.bbmt.2013.04.009	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	56	mailto:mbishop@medicine.bsd.uchicago.edu	mailto:mbishop@medicine.bsd.uchicago.edu	NNP
work_xsvwzurwvngfnj4ubi324mvlje	41	57	M.R.	M.R.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	1	Bishop	Bishop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	2	/	/	SYM
work_xsvwzurwvngfnj4ubi324mvlje	42	3	Biol	Biol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	4	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	5	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	6	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	42	7	19	19	CD
work_xsvwzurwvngfnj4ubi324mvlje	42	8	(	(	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	42	9	2013	2013	CD
work_xsvwzurwvngfnj4ubi324mvlje	42	10	)	)	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	42	11	847e850850	847e850850	CD
work_xsvwzurwvngfnj4ubi324mvlje	42	12	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	42	13	setting	set	VBG
work_xsvwzurwvngfnj4ubi324mvlje	42	14	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	42	15	11,12	11,12	CD
work_xsvwzurwvngfnj4ubi324mvlje	42	16	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	42	17	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	43	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	43	2	key	key	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	3	element	element	NN
work_xsvwzurwvngfnj4ubi324mvlje	43	4	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	43	5	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	43	6	design	design	NN
work_xsvwzurwvngfnj4ubi324mvlje	43	7	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	43	8	implementation	implementation	NN
work_xsvwzurwvngfnj4ubi324mvlje	43	9	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	10	such	such	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	11	studies	study	NNS
work_xsvwzurwvngfnj4ubi324mvlje	43	12	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	13	multi	multi	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	14	-	-	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	15	institutional	institutional	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	16	settings	setting	NNS
work_xsvwzurwvngfnj4ubi324mvlje	43	17	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	43	18	which	which	WDT
work_xsvwzurwvngfnj4ubi324mvlje	43	19	was	be	VBD
work_xsvwzurwvngfnj4ubi324mvlje	43	20	one	one	CD
work_xsvwzurwvngfnj4ubi324mvlje	43	21	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	43	22	major	major	JJ
work_xsvwzurwvngfnj4ubi324mvlje	43	23	recommendations	recommendation	NNS
work_xsvwzurwvngfnj4ubi324mvlje	43	24	from	from	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	25	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	43	26	National	National	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	27	Cancer	Cancer	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	28	Institute	Institute	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	29	’s	’s	POS
work_xsvwzurwvngfnj4ubi324mvlje	43	30	First	First	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	31	International	International	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	32	Workshop	Workshop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	33	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	34	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	43	35	Biology	Biology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	36	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	43	37	Prevention	Prevention	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	38	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	43	39	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	43	40	Treatment	Treatment	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	41	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	42	Relapse	Relapse	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	43	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	43	44	Allogeneic	Allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	45	Hematopoietic	Hematopoietic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	46	Stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	43	47	Cell	Cell	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	48	Transplantation	Transplantation	NNP
work_xsvwzurwvngfnj4ubi324mvlje	43	49	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	44	1	Thus	thus	RB
work_xsvwzurwvngfnj4ubi324mvlje	44	2	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	44	3	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	44	4	only	only	JJ
work_xsvwzurwvngfnj4ubi324mvlje	44	5	way	way	NN
work_xsvwzurwvngfnj4ubi324mvlje	44	6	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	44	7	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	44	8	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	44	9	going	go	VBG
work_xsvwzurwvngfnj4ubi324mvlje	44	10	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	44	11	determine	determine	VB
work_xsvwzurwvngfnj4ubi324mvlje	44	12	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	44	13	optimal	optimal	JJ
work_xsvwzurwvngfnj4ubi324mvlje	44	14	use	use	NN
work_xsvwzurwvngfnj4ubi324mvlje	44	15	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	44	16	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	44	17	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	44	18	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	44	19	move	move	VB
work_xsvwzurwvngfnj4ubi324mvlje	44	20	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	44	21	field	field	NN
work_xsvwzurwvngfnj4ubi324mvlje	44	22	forward	forward	RB
work_xsvwzurwvngfnj4ubi324mvlje	44	23	[	[	-LRB-
work_xsvwzurwvngfnj4ubi324mvlje	44	24	13	13	CD
work_xsvwzurwvngfnj4ubi324mvlje	44	25	]	]	-RRB-
work_xsvwzurwvngfnj4ubi324mvlje	44	26	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	45	1	So	so	CC
work_xsvwzurwvngfnj4ubi324mvlje	45	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	45	3	as	as	IN
work_xsvwzurwvngfnj4ubi324mvlje	45	4	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	45	5	step	step	VBP
work_xsvwzurwvngfnj4ubi324mvlje	45	6	back	back	RB
work_xsvwzurwvngfnj4ubi324mvlje	45	7	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	45	8	look	look	VB
work_xsvwzurwvngfnj4ubi324mvlje	45	9	across	across	IN
work_xsvwzurwvngfnj4ubi324mvlje	45	10	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	45	11	dance	dance	NN
work_xsvwzurwvngfnj4ubi324mvlje	45	12	floor	floor	NN
work_xsvwzurwvngfnj4ubi324mvlje	45	13	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	45	14	do	do	VBP
work_xsvwzurwvngfnj4ubi324mvlje	45	15	we	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	45	16	really	really	RB
work_xsvwzurwvngfnj4ubi324mvlje	45	17	find	find	VB
work_xsvwzurwvngfnj4ubi324mvlje	45	18	ourdate	ourdate	NN
work_xsvwzurwvngfnj4ubi324mvlje	45	19	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	45	20	DLI	DLI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	45	21	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	45	22	attractive	attractive	JJ
work_xsvwzurwvngfnj4ubi324mvlje	45	23	?	?	.
work_xsvwzurwvngfnj4ubi324mvlje	46	1	Maybe	maybe	RB
work_xsvwzurwvngfnj4ubi324mvlje	46	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	46	3	ifviewedwithinthe	ifviewedwithinthe	JJ
work_xsvwzurwvngfnj4ubi324mvlje	46	4	context	context	NN
work_xsvwzurwvngfnj4ubi324mvlje	46	5	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	46	6	our	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	46	7	other	other	JJ
work_xsvwzurwvngfnj4ubi324mvlje	46	8	options	option	NNS
work_xsvwzurwvngfnj4ubi324mvlje	46	9	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	46	10	recurrent	recurrent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	46	11	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	46	12	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	46	13	allo-	allo-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	46	14	geneic	geneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	46	15	hematopoietic	hematopoietic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	46	16	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	46	17	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	46	18	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	47	1	However	however	RB
work_xsvwzurwvngfnj4ubi324mvlje	47	2	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	47	3	I	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	47	4	would	would	MD
work_xsvwzurwvngfnj4ubi324mvlje	47	5	argue	argue	VB
work_xsvwzurwvngfnj4ubi324mvlje	47	6	that	that	IN
work_xsvwzurwvngfnj4ubi324mvlje	47	7	maybe	maybe	RB
work_xsvwzurwvngfnj4ubi324mvlje	47	8	it	-PRON-	PRP
work_xsvwzurwvngfnj4ubi324mvlje	47	9	is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	47	10	time	time	NN
work_xsvwzurwvngfnj4ubi324mvlje	47	11	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	47	12	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	47	13	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	47	14	community	community	NN
work_xsvwzurwvngfnj4ubi324mvlje	47	15	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	47	16	go	go	VB
work_xsvwzurwvngfnj4ubi324mvlje	47	17	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	47	18	ophthalmologist	ophthalmologist	NN
work_xsvwzurwvngfnj4ubi324mvlje	47	19	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	47	20	get	get	VB
work_xsvwzurwvngfnj4ubi324mvlje	47	21	our	-PRON-	PRP$
work_xsvwzurwvngfnj4ubi324mvlje	47	22	eyes	eye	NNS
work_xsvwzurwvngfnj4ubi324mvlje	47	23	examined	examine	VBN
work_xsvwzurwvngfnj4ubi324mvlje	47	24	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	48	1	ACKNOWLEDGMENTS	ACKNOWLEDGMENTS	NNP
work_xsvwzurwvngfnj4ubi324mvlje	48	2	Financial	financial	JJ
work_xsvwzurwvngfnj4ubi324mvlje	48	3	disclosure	disclosure	NN
work_xsvwzurwvngfnj4ubi324mvlje	48	4	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	48	5	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	48	6	authors	author	NNS
work_xsvwzurwvngfnj4ubi324mvlje	48	7	have	have	VBP
work_xsvwzurwvngfnj4ubi324mvlje	48	8	nothing	nothing	NN
work_xsvwzurwvngfnj4ubi324mvlje	48	9	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	48	10	disclose	disclose	VB
work_xsvwzurwvngfnj4ubi324mvlje	48	11	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	49	1	REFERENCES	reference	NNS
work_xsvwzurwvngfnj4ubi324mvlje	49	2	1	1	CD
work_xsvwzurwvngfnj4ubi324mvlje	49	3	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	50	1	Bar	Bar	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	2	M	M	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	50	4	Sandmaier	Sandmaier	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	5	BM	BM	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	50	7	Inamoto	Inamoto	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	8	Y	Y	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	50	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	50	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	51	1	Donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	2	lymphocyte	lymphocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	3	infusion	infusion	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	4	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	51	5	relapsed	relapse	VBN
work_xsvwzurwvngfnj4ubi324mvlje	51	6	hematological	hematological	JJ
work_xsvwzurwvngfnj4ubi324mvlje	51	7	malignancies	malignancy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	51	8	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	51	9	allogeneic	allogeneic	IN
work_xsvwzurwvngfnj4ubi324mvlje	51	10	hematopoietic	hematopoietic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	51	11	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	12	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	13	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	51	14	prognostic	prognostic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	51	15	relevance	relevance	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	16	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	51	17	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	51	18	initial	initial	JJ
work_xsvwzurwvngfnj4ubi324mvlje	51	19	CD3þ	CD3þ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	51	20	T	T	NNP
work_xsvwzurwvngfnj4ubi324mvlje	51	21	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	51	22	dose	dose	VBD
work_xsvwzurwvngfnj4ubi324mvlje	51	23	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	52	1	Biol	Biol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	52	2	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	52	3	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	52	4	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	52	5	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	53	1	2013;19:949	2013;19:949	CD
work_xsvwzurwvngfnj4ubi324mvlje	53	2	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	53	3	957	957	CD
work_xsvwzurwvngfnj4ubi324mvlje	53	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	54	1	2	2	LS
work_xsvwzurwvngfnj4ubi324mvlje	54	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	55	1	Kolb	Kolb	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	2	HJ	HJ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	55	4	Mittermüller	Mittermüller	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	5	J	J	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	55	7	Clemm	Clemm	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	8	C	C	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	55	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	55	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	56	1	Donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	56	2	leukocyte	leukocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	56	3	transfusions	transfusion	NNS
work_xsvwzurwvngfnj4ubi324mvlje	56	4	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	56	5	treatment	treatment	NN
work_xsvwzurwvngfnj4ubi324mvlje	56	6	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	56	7	recurrent	recurrent	JJ
work_xsvwzurwvngfnj4ubi324mvlje	56	8	chronic	chronic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	56	9	myelogenous	myelogenous	JJ
work_xsvwzurwvngfnj4ubi324mvlje	56	10	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	56	11	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	56	12	marrow	marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	56	13	transplant	transplant	NN
work_xsvwzurwvngfnj4ubi324mvlje	56	14	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	56	15	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	57	1	Blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	57	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	58	1	1990;76:2462	1990;76:2462	CD
work_xsvwzurwvngfnj4ubi324mvlje	58	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	58	3	2465	2465	CD
work_xsvwzurwvngfnj4ubi324mvlje	58	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	59	1	3	3	LS
work_xsvwzurwvngfnj4ubi324mvlje	59	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	60	1	Mehta	Mehta	NNP
work_xsvwzurwvngfnj4ubi324mvlje	60	2	J.	J.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	1	The	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	61	2	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	61	3	clinical	clinical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	61	4	use	use	NN
work_xsvwzurwvngfnj4ubi324mvlje	61	5	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	61	6	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	61	7	leukocyte	leukocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	61	8	infusions	infusion	NNS
work_xsvwzurwvngfnj4ubi324mvlje	61	9	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	61	10	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	61	11	treatment	treatment	NN
work_xsvwzurwvngfnj4ubi324mvlje	61	12	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	61	13	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	61	14	relapsing	relapse	VBG
work_xsvwzurwvngfnj4ubi324mvlje	61	15	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	61	16	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	17	bone	bone	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	18	marrow	marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	19	trans-	trans-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	20	plantation	plantation	NNP
work_xsvwzurwvngfnj4ubi324mvlje	61	21	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	62	1	Blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	62	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	63	1	1996;87:4010	1996;87:4010	LS
work_xsvwzurwvngfnj4ubi324mvlje	63	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	64	1	4	4	LS
work_xsvwzurwvngfnj4ubi324mvlje	64	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	65	1	Slavin	Slavin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	2	S	S	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	65	4	Naparstek	Naparstek	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	5	E	E	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	65	7	Nagler	Nagler	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	8	A	A	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	65	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	65	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	66	1	Allogeneic	allogeneic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	66	2	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	3	therapy	therapy	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	4	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	66	5	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	6	peripheral	peripheral	JJ
work_xsvwzurwvngfnj4ubi324mvlje	66	7	blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	8	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	66	9	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	66	10	recombinant	recombinant	JJ
work_xsvwzurwvngfnj4ubi324mvlje	66	11	human	human	JJ
work_xsvwzurwvngfnj4ubi324mvlje	66	12	interleukin-2	interleukin-2	NNP
work_xsvwzurwvngfnj4ubi324mvlje	66	13	to	to	TO
work_xsvwzurwvngfnj4ubi324mvlje	66	14	treat	treat	VB
work_xsvwzurwvngfnj4ubi324mvlje	66	15	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	16	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	17	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	66	18	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	66	19	bone	bone	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	20	marrow	marrow	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	21	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	66	22	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	67	1	Blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	67	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	68	1	1996;87:2195	1996;87:2195	CD
work_xsvwzurwvngfnj4ubi324mvlje	68	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	68	3	2204	2204	CD
work_xsvwzurwvngfnj4ubi324mvlje	68	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	69	1	5	5	CD
work_xsvwzurwvngfnj4ubi324mvlje	69	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	70	1	Alessandrino	alessandrino	JJ
work_xsvwzurwvngfnj4ubi324mvlje	70	2	EP	EP	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	70	4	Bernasconi	Bernasconi	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	5	P	P	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	70	7	Caldera	Caldera	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	8	D	D	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	70	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	70	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	71	1	Chemotherapy	chemotherapy	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	2	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	71	3	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	4	peripheral	peripheral	NNP
work_xsvwzurwvngfnj4ubi324mvlje	71	5	blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	6	progenitor	progenitor	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	7	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	71	8	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	71	9	acute	acute	JJ
work_xsvwzurwvngfnj4ubi324mvlje	71	10	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	11	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	71	12	early	early	JJ
work_xsvwzurwvngfnj4ubi324mvlje	71	13	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	14	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	71	15	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	71	16	bone	bone	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	17	marrow	marrow	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	18	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	71	19	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	72	1	Bone	Bone	NNP
work_xsvwzurwvngfnj4ubi324mvlje	72	2	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	72	3	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	72	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	73	1	1999;23:607	1999;23:607	CD
work_xsvwzurwvngfnj4ubi324mvlje	73	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	73	3	612	612	CD
work_xsvwzurwvngfnj4ubi324mvlje	73	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	74	1	6	6	CD
work_xsvwzurwvngfnj4ubi324mvlje	74	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	75	1	Leda	Leda	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	2	M	M	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	75	4	Ladon	Ladon	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	5	D	D	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	75	7	Pieczonka	Pieczonka	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	8	A	A	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	75	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	75	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	76	1	Donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	2	lymphocyte	lymphocyte	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	3	infusion	infusion	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	4	fol-	fol-	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	5	lowed	low	VBN
work_xsvwzurwvngfnj4ubi324mvlje	76	6	by	by	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	7	interferon	interferon	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	8	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	76	9	alpha	alpha	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	10	plus	plus	CC
work_xsvwzurwvngfnj4ubi324mvlje	76	11	low	low	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	12	dose	dose	VBD
work_xsvwzurwvngfnj4ubi324mvlje	76	13	cyclosporine	cyclosporine	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	14	A	a	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	15	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	16	modulation	modulation	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	17	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	18	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	19	CD3	CD3	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	20	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	21	activity	activity	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	22	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	23	monitoring	monitoring	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	24	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	25	minimal	minimal	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	26	residual	residual	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	27	disease	disease	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	28	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	76	29	cellular	cellular	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	30	chimerism	chimerism	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	31	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	32	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	76	33	patient	patient	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	34	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	35	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	36	hematologic	hematologic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	37	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	38	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	39	chronic	chronic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	40	myelogenous	myelogenous	JJ
work_xsvwzurwvngfnj4ubi324mvlje	76	41	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	76	42	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	76	43	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	44	bone	bone	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	45	marrow	marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	46	trans-	trans-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	47	plantation	plantation	NNP
work_xsvwzurwvngfnj4ubi324mvlje	76	48	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	77	1	Leuk	Leuk	NNP
work_xsvwzurwvngfnj4ubi324mvlje	77	2	Res	Res	NNP
work_xsvwzurwvngfnj4ubi324mvlje	77	3	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	78	1	2001;25:353	2001;25:353	CD
work_xsvwzurwvngfnj4ubi324mvlje	78	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	78	3	357	357	CD
work_xsvwzurwvngfnj4ubi324mvlje	78	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	79	1	7	7	LS
work_xsvwzurwvngfnj4ubi324mvlje	79	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	80	1	Levine	Levine	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	2	JE	JE	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	80	4	Braun	Braun	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	5	T	T	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	80	7	Penza	Penza	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	8	SL	SL	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	80	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	80	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	81	1	Prospective	prospective	JJ
work_xsvwzurwvngfnj4ubi324mvlje	81	2	trial	trial	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	3	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	81	4	chemotherapy	chemotherapy	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	5	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	81	6	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	7	leukocyte	leukocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	8	infusions	infusion	NNS
work_xsvwzurwvngfnj4ubi324mvlje	81	9	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	81	10	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	11	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	81	12	advanced	advanced	JJ
work_xsvwzurwvngfnj4ubi324mvlje	81	13	myeloid	myeloid	JJ
work_xsvwzurwvngfnj4ubi324mvlje	81	14	malignancies	malignancy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	81	15	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	81	16	allogeneic	allogeneic	IN
work_xsvwzurwvngfnj4ubi324mvlje	81	17	stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	18	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	81	19	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	20	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	81	21	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	82	1	J	J	NNP
work_xsvwzurwvngfnj4ubi324mvlje	82	2	Clin	Clin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	82	3	Oncol	Oncol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	82	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	83	1	2002;20:405	2002;20:405	CD
work_xsvwzurwvngfnj4ubi324mvlje	83	2	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	83	3	412	412	CD
work_xsvwzurwvngfnj4ubi324mvlje	83	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	84	1	8	8	LS
work_xsvwzurwvngfnj4ubi324mvlje	84	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	85	1	Collins	Collins	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	2	RH	RH	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	3	Jr	Jr	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	4	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	85	5	Shpilberg	Shpilberg	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	6	O	o	UH
work_xsvwzurwvngfnj4ubi324mvlje	85	7	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	85	8	Drobyski	Drobyski	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	9	WR	WR	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	85	11	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	12	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	85	13	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	86	1	Donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	2	leukocyte	leukocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	3	infu-	infu-	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	4	sions	sion	NNS
work_xsvwzurwvngfnj4ubi324mvlje	86	5	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	86	6	140	140	CD
work_xsvwzurwvngfnj4ubi324mvlje	86	7	patients	patient	NNS
work_xsvwzurwvngfnj4ubi324mvlje	86	8	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	86	9	relapsed	relapsed	JJ
work_xsvwzurwvngfnj4ubi324mvlje	86	10	malignancy	malignancy	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	11	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	86	12	allogeneic	allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	86	13	bone	bone	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	14	marrow	marrow	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	15	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	86	16	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	87	1	J	J	NNP
work_xsvwzurwvngfnj4ubi324mvlje	87	2	Clin	Clin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	87	3	Oncol	Oncol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	87	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	88	1	1997;15:433	1997;15:433	CD
work_xsvwzurwvngfnj4ubi324mvlje	88	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	88	3	444	444	CD
work_xsvwzurwvngfnj4ubi324mvlje	88	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	89	1	9	9	CD
work_xsvwzurwvngfnj4ubi324mvlje	89	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	90	1	Schmid	Schmid	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	2	C	C	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	90	4	Labopin	Labopin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	5	M	M	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	90	7	Nagler	Nagler	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	8	A	A	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	90	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	12	.	.	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	13	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	90	14	EBMT	EBMT	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	15	Acute	Acute	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	16	Leukemia	Leukemia	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	17	Working	Working	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	18	Party	Party	NNP
work_xsvwzurwvngfnj4ubi324mvlje	90	19	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	91	1	Donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	2	lymphocyte	lymphocyte	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	3	infusion	infusion	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	4	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	5	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	91	6	treatment	treatment	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	7	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	8	first	first	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	9	hemato-	hemato-	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	10	logical	logical	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	11	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	12	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	13	allogeneic	allogeneic	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	14	stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	15	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	91	16	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	17	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	18	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	19	adults	adult	NNS
work_xsvwzurwvngfnj4ubi324mvlje	91	20	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	21	acute	acute	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	22	myeloid	myeloid	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	23	leukemia	leukemia	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	24	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	91	25	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	91	26	retrospective	retrospective	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	27	risk	risk	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	28	factors	factor	NNS
work_xsvwzurwvngfnj4ubi324mvlje	91	29	analysis	analysis	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	30	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	91	31	comparison	comparison	NN
work_xsvwzurwvngfnj4ubi324mvlje	91	32	with	with	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	33	other	other	JJ
work_xsvwzurwvngfnj4ubi324mvlje	91	34	strategies	strategy	NNS
work_xsvwzurwvngfnj4ubi324mvlje	91	35	by	by	IN
work_xsvwzurwvngfnj4ubi324mvlje	91	36	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	91	37	EBMT	EBMT	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	38	Acute	Acute	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	39	Leukemia	Leukemia	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	40	Working	Working	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	41	Party	Party	NNP
work_xsvwzurwvngfnj4ubi324mvlje	91	42	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	92	1	J	J	NNP
work_xsvwzurwvngfnj4ubi324mvlje	92	2	Clin	Clin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	92	3	Oncol	Oncol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	92	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	93	1	2007;25:4938	2007;25:4938	CD
work_xsvwzurwvngfnj4ubi324mvlje	93	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	93	3	4945	4945	CD
work_xsvwzurwvngfnj4ubi324mvlje	93	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	94	1	10	10	CD
work_xsvwzurwvngfnj4ubi324mvlje	94	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	95	1	Porter	Porter	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	2	DL	DL	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	95	4	Alyea	Alyea	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	5	EP	EP	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	95	7	Antin	Antin	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	8	JH	JH	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	95	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	95	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	96	1	NCI	NCI	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	2	First	First	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	3	International	International	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	4	Workshop	Workshop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	5	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	6	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	96	7	Biology	Biology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	8	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	96	9	Prevention	Prevention	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	96	11	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	96	12	Treatment	Treatment	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	13	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	14	Relapse	Relapse	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	15	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	16	Allogeneic	Allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	17	Hematopoietic	Hematopoietic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	18	Stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	96	19	Cell	Cell	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	20	Transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	96	21	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	96	22	Report	report	NN
work_xsvwzurwvngfnj4ubi324mvlje	96	23	from	from	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	24	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	96	25	Committee	Committee	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	26	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	27	Treatment	Treatment	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	28	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	29	Relapse	Relapse	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	30	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	96	31	Allogeneic	Allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	32	Hematopoietic	Hematopoietic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	33	Stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	96	34	Cell	Cell	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	35	Transplantation	Transplantation	NNP
work_xsvwzurwvngfnj4ubi324mvlje	96	36	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	97	1	Biol	Biol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	97	2	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	97	3	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	97	4	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	97	5	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	98	1	2010;16:1467	2010;16:1467	CD
work_xsvwzurwvngfnj4ubi324mvlje	98	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	98	3	1503	1503	CD
work_xsvwzurwvngfnj4ubi324mvlje	98	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	99	1	11	11	CD
work_xsvwzurwvngfnj4ubi324mvlje	99	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	100	1	Porter	Porter	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	2	DL	DL	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	100	4	Levine	Levine	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	5	BL	BL	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	100	7	Kalos	Kalos	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	8	M	M	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	100	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	100	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	101	1	Chimeric	Chimeric	NNP
work_xsvwzurwvngfnj4ubi324mvlje	101	2	antigen	antigen	NNP
work_xsvwzurwvngfnj4ubi324mvlje	101	3	receptoremodi-	receptoremodi-	NN
work_xsvwzurwvngfnj4ubi324mvlje	101	4	fied	fie	VBD
work_xsvwzurwvngfnj4ubi324mvlje	101	5	T	T	NNP
work_xsvwzurwvngfnj4ubi324mvlje	101	6	cells	cell	NNS
work_xsvwzurwvngfnj4ubi324mvlje	101	7	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	101	8	chronic	chronic	JJ
work_xsvwzurwvngfnj4ubi324mvlje	101	9	lymphoid	lymphoid	NN
work_xsvwzurwvngfnj4ubi324mvlje	101	10	leukemia	leukemia	NN
work_xsvwzurwvngfnj4ubi324mvlje	101	11	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	102	1	N	N	NNP
work_xsvwzurwvngfnj4ubi324mvlje	102	2	Engl	Engl	NNP
work_xsvwzurwvngfnj4ubi324mvlje	102	3	J	J	NNP
work_xsvwzurwvngfnj4ubi324mvlje	102	4	Med	Med	NNP
work_xsvwzurwvngfnj4ubi324mvlje	102	5	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	103	1	2011;365	2011;365	CD
work_xsvwzurwvngfnj4ubi324mvlje	103	2	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	103	3	725	725	CD
work_xsvwzurwvngfnj4ubi324mvlje	103	4	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	103	5	733	733	CD
work_xsvwzurwvngfnj4ubi324mvlje	103	6	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	104	1	12	12	CD
work_xsvwzurwvngfnj4ubi324mvlje	104	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	105	1	Hardy	Hardy	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	2	NM	NM	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	105	4	Fellowes	Fellowes	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	5	V	V	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	6	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	105	7	Rose	Rose	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	8	JJ	JJ	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	9	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	105	10	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	11	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	105	12	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	106	1	Costimulated	costimulated	JJ
work_xsvwzurwvngfnj4ubi324mvlje	106	2	tumor	tumor	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	3	-	-	HYPH
work_xsvwzurwvngfnj4ubi324mvlje	106	4	infiltrating	infiltrate	VBG
work_xsvwzurwvngfnj4ubi324mvlje	106	5	lymphocytes	lymphocyte	NNS
work_xsvwzurwvngfnj4ubi324mvlje	106	6	are	be	VBP
work_xsvwzurwvngfnj4ubi324mvlje	106	7	a	a	DT
work_xsvwzurwvngfnj4ubi324mvlje	106	8	feasible	feasible	JJ
work_xsvwzurwvngfnj4ubi324mvlje	106	9	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	106	10	safe	safe	JJ
work_xsvwzurwvngfnj4ubi324mvlje	106	11	alternative	alternative	JJ
work_xsvwzurwvngfnj4ubi324mvlje	106	12	donor	donor	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	13	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	14	therapy	therapy	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	15	for	for	IN
work_xsvwzurwvngfnj4ubi324mvlje	106	16	relapse	relapse	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	17	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	106	18	allogeneic	allogeneic	IN
work_xsvwzurwvngfnj4ubi324mvlje	106	19	stem	stem	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	20	cell	cell	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	21	transplantation	transplantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	106	22	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	107	1	Blood	blood	NN
work_xsvwzurwvngfnj4ubi324mvlje	107	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	108	1	2012;119	2012;119	CD
work_xsvwzurwvngfnj4ubi324mvlje	108	2	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	108	3	2956	2956	CD
work_xsvwzurwvngfnj4ubi324mvlje	108	4	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	108	5	2959	2959	CD
work_xsvwzurwvngfnj4ubi324mvlje	108	6	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	109	1	13	13	CD
work_xsvwzurwvngfnj4ubi324mvlje	109	2	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	110	1	Bishop	Bishop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	2	MR	MR	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	3	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	110	4	Alyea	Alyea	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	5	EP	EP	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	6	3rd	3rd	NN
work_xsvwzurwvngfnj4ubi324mvlje	110	7	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	110	8	Cairo	Cairo	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	9	MS	MS	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	10	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	110	11	et	et	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	12	al	al	NNP
work_xsvwzurwvngfnj4ubi324mvlje	110	13	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	111	1	National	National	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	2	Cancer	Cancer	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	3	Institute	Institute	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	4	’s	’s	POS
work_xsvwzurwvngfnj4ubi324mvlje	111	5	First	First	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	6	International	International	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	7	Workshop	Workshop	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	8	on	on	IN
work_xsvwzurwvngfnj4ubi324mvlje	111	9	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	111	10	Biology	Biology	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	11	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	111	12	Prevention	Prevention	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	13	,	,	,
work_xsvwzurwvngfnj4ubi324mvlje	111	14	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	111	15	Treat-	Treat-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	16	ment	ment	NN
work_xsvwzurwvngfnj4ubi324mvlje	111	17	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	111	18	Relapse	Relapse	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	19	after	after	IN
work_xsvwzurwvngfnj4ubi324mvlje	111	20	Allogeneic	Allogeneic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	21	Hematopoietic	Hematopoietic	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	22	Stem	Stem	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	23	Cell	Cell	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	24	Trans-	Trans-	NNP
work_xsvwzurwvngfnj4ubi324mvlje	111	25	plantation	plantation	NN
work_xsvwzurwvngfnj4ubi324mvlje	111	26	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	111	27	summary	summary	NN
work_xsvwzurwvngfnj4ubi324mvlje	111	28	and	and	CC
work_xsvwzurwvngfnj4ubi324mvlje	111	29	recommendations	recommendation	NNS
work_xsvwzurwvngfnj4ubi324mvlje	111	30	from	from	IN
work_xsvwzurwvngfnj4ubi324mvlje	111	31	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	111	32	organizing	organize	VBG
work_xsvwzurwvngfnj4ubi324mvlje	111	33	committee	committee	NN
work_xsvwzurwvngfnj4ubi324mvlje	111	34	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	112	1	Biol	Biol	NNP
work_xsvwzurwvngfnj4ubi324mvlje	112	2	Blood	Blood	NNP
work_xsvwzurwvngfnj4ubi324mvlje	112	3	Marrow	Marrow	NNP
work_xsvwzurwvngfnj4ubi324mvlje	112	4	Transplant	Transplant	NNP
work_xsvwzurwvngfnj4ubi324mvlje	112	5	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	113	1	2011;17:443	2011;17:443	CD
work_xsvwzurwvngfnj4ubi324mvlje	113	2	-	-	SYM
work_xsvwzurwvngfnj4ubi324mvlje	113	3	454	454	CD
work_xsvwzurwvngfnj4ubi324mvlje	113	4	.	.	.
work_xsvwzurwvngfnj4ubi324mvlje	114	1	Donor	Donor	NNP
work_xsvwzurwvngfnj4ubi324mvlje	114	2	Lymphocyte	Lymphocyte	NNP
work_xsvwzurwvngfnj4ubi324mvlje	114	3	Infusion	Infusion	NNP
work_xsvwzurwvngfnj4ubi324mvlje	114	4	:	:	:
work_xsvwzurwvngfnj4ubi324mvlje	114	5	Beauty	beauty	NN
work_xsvwzurwvngfnj4ubi324mvlje	114	6	Is	be	VBZ
work_xsvwzurwvngfnj4ubi324mvlje	114	7	in	in	IN
work_xsvwzurwvngfnj4ubi324mvlje	114	8	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	114	9	Eye	Eye	NNP
work_xsvwzurwvngfnj4ubi324mvlje	114	10	of	of	IN
work_xsvwzurwvngfnj4ubi324mvlje	114	11	the	the	DT
work_xsvwzurwvngfnj4ubi324mvlje	114	12	Beholder	Beholder	NNP
work_xsvwzurwvngfnj4ubi324mvlje	114	13	Acknowledgments	Acknowledgments	NNPS
work_xsvwzurwvngfnj4ubi324mvlje	114	14	References	References	NNPS